Transcriptional responses in Parascaris univalens after in vitro exposure to ivermectin, pyrantel citrate and thiabendazole.
Anthelmintic resistance
Differential expression
RNA sequencing
Transcriptome
lgc-37
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
09 Jul 2020
09 Jul 2020
Historique:
received:
17
03
2020
accepted:
02
07
2020
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
6
3
2021
Statut:
epublish
Résumé
Parascaris univalens is a pathogenic parasite of foals and yearlings worldwide. In recent years, Parascaris spp. worms have developed resistance to several of the commonly used anthelmintics, though currently the mechanisms behind this development are unknown. The aim of this study was to investigate the transcriptional responses in adult P. univalens worms after in vitro exposure to different concentrations of three anthelmintic drugs, focusing on drug targets and drug metabolising pathways. Adult worms were collected from the intestines of two foals at slaughter. The foals were naturally infected and had never been treated with anthelmintics. Worms were incubated in cell culture media containing different concentrations of either ivermectin (10 All worms were alive at the end of the incubation but showed varying degrees of viability depending on the drug and concentration used. Differential expression (Padj < 0.05 and log2 fold change ≥ 1 or ≤ - 1) analysis showed similarities and differences in the transcriptional response after exposure to the different drug classes. Candidate genes upregulated or downregulated in drug exposed worms include members of the phase I metabolic pathway short-chain dehydrogenase/reductase superfamily (SDR), flavin containing monooxygenase superfamily (FMO) and cytochrome P450-family (CYP), as well as members of the membrane transporters major facilitator superfamily (MFS) and solute carrier superfamily (SLC). Generally, different targets of the anthelmintics used were found to be upregulated and downregulated in an unspecific pattern after drug exposure, apart from the GABA receptor subunit lgc-37, which was upregulated only in worms exposed to 10 To our knowledge, this is the first time the expression of lgc-37 and members of the FMO, SDR, MFS and SLC superfamilies have been described in P. univalens and future work should be focused on characterising these candidate genes to further explore their potential involvement in drug metabolism and anthelmintic resistance.
Sections du résumé
BACKGROUND
BACKGROUND
Parascaris univalens is a pathogenic parasite of foals and yearlings worldwide. In recent years, Parascaris spp. worms have developed resistance to several of the commonly used anthelmintics, though currently the mechanisms behind this development are unknown. The aim of this study was to investigate the transcriptional responses in adult P. univalens worms after in vitro exposure to different concentrations of three anthelmintic drugs, focusing on drug targets and drug metabolising pathways.
METHODS
METHODS
Adult worms were collected from the intestines of two foals at slaughter. The foals were naturally infected and had never been treated with anthelmintics. Worms were incubated in cell culture media containing different concentrations of either ivermectin (10
RESULTS
RESULTS
All worms were alive at the end of the incubation but showed varying degrees of viability depending on the drug and concentration used. Differential expression (Padj < 0.05 and log2 fold change ≥ 1 or ≤ - 1) analysis showed similarities and differences in the transcriptional response after exposure to the different drug classes. Candidate genes upregulated or downregulated in drug exposed worms include members of the phase I metabolic pathway short-chain dehydrogenase/reductase superfamily (SDR), flavin containing monooxygenase superfamily (FMO) and cytochrome P450-family (CYP), as well as members of the membrane transporters major facilitator superfamily (MFS) and solute carrier superfamily (SLC). Generally, different targets of the anthelmintics used were found to be upregulated and downregulated in an unspecific pattern after drug exposure, apart from the GABA receptor subunit lgc-37, which was upregulated only in worms exposed to 10
CONCLUSIONS
CONCLUSIONS
To our knowledge, this is the first time the expression of lgc-37 and members of the FMO, SDR, MFS and SLC superfamilies have been described in P. univalens and future work should be focused on characterising these candidate genes to further explore their potential involvement in drug metabolism and anthelmintic resistance.
Identifiants
pubmed: 32646465
doi: 10.1186/s13071-020-04212-0
pii: 10.1186/s13071-020-04212-0
pmc: PMC7346371
doi:
Substances chimiques
Anthelmintics
0
pyrantel citrate
1YXE665Z2S
Pyrantel
4QIH0N49E7
Ivermectin
70288-86-7
Thiabendazole
N1Q45E87DT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342Subventions
Organisme : Svenska Forskningsrådet Formas
ID : 942-2015-508
Références
Mol Biochem Parasitol. 1994 Feb;63(2):299-303
pubmed: 7911975
Parasitology. 2007;134(Pt 8):1093-104
pubmed: 17608969
Parasitology. 2018 Dec 18;:1-9
pubmed: 30561286
Trends Parasitol. 2016 Jun;32(6):481-491
pubmed: 26968642
Parasitol Res. 2008 Jul;103(2):287-91
pubmed: 18470536
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
Vet Parasitol. 2014 Mar 17;201(1-2):1-8
pubmed: 24485565
Vet Parasitol. 2019 Sep;273:52-59
pubmed: 31442894
Vet Parasitol. 2014 Oct 15;205(3-4):575-80
pubmed: 25224788
Mol Biochem Parasitol. 2002 Apr 9;120(2):297-300
pubmed: 11897135
Trends Parasitol. 2009 Jul;25(7):328-35
pubmed: 19541539
Parasitol Today. 1990 Apr;6(4):112-5
pubmed: 15463312
Drug Metab Pharmacokinet. 2006 Feb;21(1):1-18
pubmed: 16547389
Parasit Vectors. 2014 Aug 29;7:410
pubmed: 25175357
Vet Parasitol. 2013 Sep 23;196(3-4):373-81
pubmed: 23587403
Genome Biol. 2014;15(12):550
pubmed: 25516281
FEBS J. 2010 May;277(10):2375-86
pubmed: 20423462
Int J Parasitol. 2016 Sep;46(10):621-30
pubmed: 27179994
Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):420-429
pubmed: 30293057
Pharmacogenet Genomics. 2010 Jul;20(7):414-25
pubmed: 20531256
Int J Parasitol. 2011 Aug 1;41(9):935-42
pubmed: 21683705
Vet Parasitol. 2007 Mar 31;144(3-4):313-20
pubmed: 17101226
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Int J Parasitol Drugs Drug Resist. 2014 Aug 13;4(3):164-84
pubmed: 25516826
Exp Mol Pathol. 2007 Apr;82(2):104-9
pubmed: 17398281
Mol Biochem Parasitol. 2016 Jan-Feb;205(1-2):22-8
pubmed: 26880419
Vet Parasitol. 2017 Apr 30;238:43-48
pubmed: 28342672
N Z Vet J. 2006 Dec;54(6):338-43
pubmed: 17151735
Vet Parasitol. 2008 Feb 14;151(2-4):242-8
pubmed: 18054171
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Mol Biochem Parasitol. 2010 Jun;171(2):74-80
pubmed: 20211658
Mol Biochem Parasitol. 1998 Mar 15;91(2):327-35
pubmed: 9566525
Parasit Vectors. 2009 Sep 25;2 Suppl 2:S8
pubmed: 19778469
Genome Res. 2017 Dec;27(12):2001-2014
pubmed: 29118011
Vet Parasitol. 2018 Dec 15;264:69-73
pubmed: 30503095
PLoS One. 2010 Sep 03;5(9):e12564
pubmed: 20838440
Biochem Pharmacol. 1996 Jan 26;51(2):117-23
pubmed: 8615879
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Parasitol Res. 2014 Dec;113(12):4485-90
pubmed: 25231078
Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):362-369
pubmed: 29035734
Int J Parasitol. 2011 Aug 1;41(9):951-7
pubmed: 21683704
Mol Biochem Parasitol. 2013 Jul;190(1):38-43
pubmed: 23685342
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:13-29
pubmed: 31542693
J Clin Invest. 1997 Sep 1;100(5):1282-93
pubmed: 9276747
Int J Parasitol. 2009 Mar;39(4):435-41
pubmed: 18823982
Parasitology. 2020 May;147(6):659-666
pubmed: 32046800
Mol Genet Genomics. 2001 Dec;266(4):556-63
pubmed: 11810226
Vet Q. 2017 Dec;37(1):200-205
pubmed: 28537782
J Neurochem. 2002 Nov;83(4):870-8
pubmed: 12421359
Int J Parasitol Drugs Drug Resist. 2016 Aug;6(2):103-15
pubmed: 27164439
Parasitology. 2005 Oct;131(Pt 4):501-10
pubmed: 16174415
Parasit Vectors. 2014 Sep 04;7:428
pubmed: 25190631
PLoS One. 2017 Nov 3;12(11):e0185182
pubmed: 29099835
Mol Biol Evol. 2011 Apr;28(4):1531-41
pubmed: 21186191
PLoS One. 2013 Apr 24;8(4):e61635
pubmed: 23637871
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Chem Biol Interact. 2011 May 30;191(1-3):75-82
pubmed: 21300042
Microbiol Rev. 1996 Dec;60(4):575-608
pubmed: 8987357
Vet Rec. 2002 Mar 2;150(9):279-81
pubmed: 11924584